Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

Colossal Biosciences is reportedly in talks to raise fresh capital at a $20 billion to $30 billion valuation, up from $10.2 billion about 16 months ago. The company has begun generating revenue through conservation technology, government partnerships, and spinouts including Form Bio, Breaking, and Astromech, while continuing work on de-extinction projects such as the mammoth and dodo.

The reported valuation jump suggests investors are increasingly treating Colossal as a broader synthetic biology platform rather than a speculative de-extinction bet. Its mix of government customers, biotech spinouts, and potential biodiversity-credit revenue points to a trend where moonshot life-sciences companies commercialize enabling technologies before their headline goals are achieved.